Haldol Decanoas (Haloperidol Decanoate)

Haloperidol decanoate injection is indicated for several psychiatric indications where long‑acting antipsychotic therapy is appropriate.

• Maintenance therapy for adult patients with schizophrenia to reduce relapse risk.
• Treatment of acute psychotic episodes when a rapid, sustained effect is desired.
• Adjunctive management of Tourette syndrome, particularly in patients with refractory tics.
• Long‑term control of chronic psychosis in individuals with poor oral medication adherence.
• Relapse prevention in patients who have achieved stability on oral haloperidol.
• Use in combination with oral antipsychotics during transition to depot therapy.

Side effects of haloperidol decanoate vary in frequency and severity, reflecting its dopamine‑blocking activity and the long‑acting depot formulation, which maintains steady plasma concentrations over weeks.

Common

• Drowsiness, sedation, or general fatigue that may affect daily activities.
• Extrapyramidal symptoms such as tremor, muscle rigidity, akathisia, or mild dystonia.
• Anticholinergic effects including dry mouth, constipation, blurred vision, or urinary retention.
• Metabolic changes like modest weight gain, increased appetite, or elevated cholesterol levels.

Serious

• Neuroleptic malignant syndrome, a rare but potentially fatal reaction characterized by high fever, muscle rigidity, autonomic instability, and altered mental status.
• Tardive dyskinesia, presenting as persistent involuntary movements of the face, tongue, or limbs after prolonged exposure.
• Severe cardiovascular events such as marked hypotension, arrhythmias, or QT‑interval prolongation.

Precautions for haloperidol decanoate address patient selection, monitoring requirements, and conditions that may increase risk of adverse outcomes.

• Assess for a history of cardiovascular disease, arrhythmias, or prolonged QT interval before initiating therapy.
• Evaluate for prior extrapyramidal reactions or tardive dyskinesia, especially in long‑term antipsychotic users.
• Use cautiously in patients with hepatic or renal impairment, adjusting dose as clinically indicated.
• Monitor blood pressure, heart rate, and ECG periodically during treatment.
• Screen for signs of neuroleptic malignant syndrome, particularly during the first weeks after injection.
• Counsel patients about the potential for sedation and advise against operating heavy machinery until they know how they respond.
• Discuss pregnancy and breastfeeding considerations with women of childbearing potential, as safety data are limited.

Haloperidol decanoate can interact with several medications, influencing its efficacy or increasing the risk of toxicity.

Avoid

• Concurrent use with other dopamine antagonists or high‑potency antipsychotics, which may amplify extrapyramidal effects.
• Co‑administration with drugs that significantly prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.

Use with caution

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) that can raise haloperidol plasma levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce drug exposure.
• CNS depressants, including benzodiazepines or opioids, which can enhance sedation.
• Anticholinergic agents, which may mask early signs of extrapyramidal symptoms.